Skip to content
DraconiticResearch
Search Sources API
194,164 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Gastroenterology

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation — a systematic review and meta-analysis with GRADE assessment

  • Menna M. Aboelkhier1
  • Ibrahim Suleiman Elnaggar2
  • Nourhan Yasser Elsamahy2
  • Fatima Breim3
  • Alaa A. Youssef2
  • Ahmed Reda Alsayed2
  1. 1Master’s Program, Faculty of Science, Cairo University, Cairo, Egypt
  2. 2Faculty of Medicine, Tanta University, Tanta, Egypt
  3. 3Department of Obstetrics and Gynecology, University of Aleppo, Aleppo, Syria
Read full textDOICite

Abstract

Background: Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are prevalent gastrointestinal disorders with limited effective treatment options. CIC affects approximately 14% of the population worldwide, particularly women, and is marked by difficult defecation, while IBS-C also includes abdominal pain as a core of symptom. Plecanatide, a guanylate cyclase-C (GC-C) agonist approved in 2017, has shown promise in improving stool consistency and symptoms; however, its optimal therapeutic dose remains unclear.

Methods: A comprehensive literature search was conducted through (PubMed, Cochrane CENTRAL, Scopus, Web of Science, and Embase) for randomized controlled trials comparing plecanatide with placebo until August 2025. Primary outcomes included changes in complete spontaneous bowel movements (CSBMs), spontaneous bowel movements (SBMs), and stool consistency.

Results: Plecanatide significantly increased the changes in complete spontaneous bowel movements (CSBMs) across all reported doses with mean differences (MDs) of (0.75, 0.92, 0.80, and 1.00, (P < 0.00001), with the greatest improvement observed at the 9 mg dose. Moreover, spontaneous bowel movements (SBMs) improved significantly at 1, 3, and 6 mg, with (MDs: 0.97, 1.50, and 1.58, (P < 0.00001). Stool consistency and reduction in abdominal pain and bloating were observed particularly at 3–6 mg. Furthermore, plecanatide demonstrated consistent efficacy across all doses, with both 1 mg and 9 mg showing significantly greater improvements in CSBMs and SBMs compared to the 0.3 mg dose. Diarrhea was the most frequent adverse event and the primary reason for treatment discontinuation, while other safety outcomes were not significantly affected.

Conclusion: Plecanatide is generally well-tolerated in the treatment of CIC and IBS-C, with the 3 mg dose, offering the best balance between efficacy and safety. This meta-analysis supports its use as a viable treatment option, though diarrhea remains a dose-related concern.

Trial registration: This systematic review and meta-analysis was registered prospectively with PROSPERO (Registration number: CRD420251066097, Date of registration: 2025-6-10).

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05112-w.

Related

  1. Patterns and predictors of surgical management in pediatric chronic idiopathic constipation.
    Prisca C Obidike, Katlyn A Droke, Grant F Williams +7
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Nursing interventions for pediatric functional constipation: a systematic review of evidence and clinical implications
    Peiman Prandeh Afshar, Belal Mahmoud AlWadi, Fatemeh Dehghan +1
    BMC NursingPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMCDOAJ
  3. Paraspinal mechanical muscle activity assessment during gait in adolescent idiopathic scoliosis using mechanomyography
    Hanwen Lu, Qichao Ma, Fan Feng +10
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Surgery & anaesthesiaCrossref
  4. Efficacy of Magnesium Supplementation in Functional Constipation: A Systematic Review.
    Hasan Kadhem, Ward Alasfoor, Mohamed Saeed Ali +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. The impact of osteoporosis on spinal biomechanical stability in adolescent idiopathic scoliosis: a narrative review of finite element analysis and bone mineral density assessment.
    Zhaomeng Hou, Jiaojiao Wu, Hua Lu +2
    Frontiers in bioengineering and biotechnologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{aboelkhier2026relief,
  title = {{Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation — a systematic review and meta-analysis with GRADE assessment}},
  author = {Menna M. Aboelkhier and Ibrahim Suleiman Elnaggar and Nourhan Yasser Elsamahy and Fatima Breim and Alaa A. Youssef and Ahmed Reda Alsayed},
  journal = {BMC Gastroenterology},
  year = {2026},
  month = oct,
  doi = {10.1186/s12876-026-05112-w},
  url = {https://doi.org/10.1186/s12876-026-05112-w},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation — a systematic review and meta-analysis with GRADE assessment
AU  - Menna M. Aboelkhier
AU  - Ibrahim Suleiman Elnaggar
AU  - Nourhan Yasser Elsamahy
AU  - Fatima Breim
AU  - Alaa A. Youssef
AU  - Ahmed Reda Alsayed
PY  - 2026
DA  - 2026/10/01
JO  - BMC Gastroenterology
DO  - 10.1186/s12876-026-05112-w
UR  - https://doi.org/10.1186/s12876-026-05112-w
AB  - Background: Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are prevalent gastrointestinal disorders with limited effective treatment options. CIC affects approximately 14% of the population worldwide, particularly women, and is marked by difficult defecation, while IBS-C also includes abdominal pain as a core of symptom. Plecanatide, a guanylate cyclase-C (GC-C) agonist approved in 2017, has shown promise in improving stool consistency and symptoms; however, its optimal therapeutic dose remains unclear.  Methods: A comprehensive literature search was conducted through (PubMed, Cochrane CENTRAL, Scopus, Web of Science, and Embase) for randomized controlled trials comparing plecanatide with placebo until August 2025. Primary outcomes included changes in complete spontaneous bowel movements (CSBMs), spontaneous bowel movements (SBMs), and stool consistency.  Results: Plecanatide significantly increased the changes in complete spontaneous bowel movements (CSBMs) across all reported doses with mean differences (MDs) of (0.75, 0.92, 0.80, and 1.00, (P < 0.00001), with the greatest improvement observed at the 9 mg dose. Moreover, spontaneous bowel movements (SBMs) improved significantly at 1, 3, and 6 mg, with (MDs: 0.97, 1.50, and 1.58, (P < 0.00001). Stool consistency and reduction in abdominal pain and bloating were observed particularly at 3–6 mg. Furthermore, plecanatide demonstrated consistent efficacy across all doses, with both 1 mg and 9 mg showing significantly greater improvements in CSBMs and SBMs compared to the 0.3 mg dose. Diarrhea was the most frequent adverse event and the primary reason for treatment discontinuation, while other safety outcomes were not significantly affected.  Conclusion: Plecanatide is generally well-tolerated in the treatment of CIC and IBS-C, with the 3 mg dose, offering the best balance between efficacy and safety. This meta-analysis supports its use as a viable treatment option, though diarrhea remains a dose-related concern.  Trial registration: This systematic review and meta-analysis was registered prospectively with PROSPERO (Registration number: CRD420251066097, Date of registration: 2025-6-10).  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05112-w.
SN  - 1471-230X
ER  -